

**Supplementary figure 5. T cell phenotyping in patients with uveitis before and during treatment with adalimumab and in healthy controls.**

w0: patients before induction of adalimumab treatment; w6: patients after 6 weeks of adalimumab treatment; w12: patients after 12 weeks of adalimumab treatment. Percentage of cells positive for either CD4 or CD3 and the respective additional surface markers / transcription factors, and level of expression of respective surface markers on CD4+ or CD3+ cells (mean fluorescence intensity, MFI).